Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,308.00-0.33%ETH$2,279.53+0.07%GOLD$3,944.70-0.63%OIL$97.22+0.79%
Smart Investors Daily
SID Premium
AZ

AMEX · AZTR

Azitra, Inc.

Healthcare · Biotechnology

$0.84

Up+$0.07 (+8.72%)

Updated Nov 3, 2026, 1:22 PM

SID Score

6.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.72M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.05 – $2.13
Volume
523.07K
Avg. volume
2.58M

Price performance · AZTR

AZTR price history

1M range · 13 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

AZTR closed at $0.84 after 13 trading sessions, up 512.23% for the selected period.

Last close
$0.84
Period change
+512.23%
Period low
$0.07
Period high
$1.53
Daily close
View OHLC price history
AZTR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$0.7686$0.90$0.7404$0.8363523.07K
Oct 30, 2026$0.712$0.79$0.6511$0.7692787.87K
Oct 29, 2026$0.8632$0.8725$0.732$0.75711.13M
Oct 28, 2026$1.09$1.1095$0.86$0.90462.69M
Oct 27, 2026$1.21$1.32$1.05$1.127.84M
Oct 26, 2026$1.04$2.1299$0.9062$1.53148.42M
Oct 13, 2026$0.1207$0.1213$0.0518$0.07152.67M
Oct 12, 2026$0.1298$0.1318$0.1157$0.1176476.78K
Oct 9, 2026$0.13$0.132$0.1262$0.1299323K
Oct 8, 2026$0.1334$0.1346$0.13$0.132287.14K
Oct 7, 2026$0.133$0.1369$0.13$0.132290.37K
Oct 6, 2026$0.1399$0.1399$0.13$0.13413.23K
Oct 5, 2026$0.138$0.1398$0.1298$0.1366622.88K

Latest AZTR news

The latest Smart Investors Daily articles mentioning AZTR.

Stock researchCompany · Overview

AZTR research

Overview

Company profile and research snapshot.

Company profile

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$2.75
Implied upside
—
Analysts
7
AZTR recent ratings
DateFirmRatingTarget
Sep 24, 2025Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors

Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced amendments to its ongoing Phase 1/2 clinical trial of ATR04-484 that significantly expand patient eligibility to include individuals with rash associated with KRAS and MEK inhibitors. The expanded eligibility also includes patients with neurofibromatosis type 1 (NF1) with rash associated with MEK inhibitor

Yahoo · Oct 27, 2026

Top Premarket Decliners

Datavault AI (DVLT) stock was down 40% in Tuesday's premarket activity after the company announced i

Yahoo · Oct 26, 2026

Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Cofounder and Chief Operating Officer, Travis Whitfill, PhD, MPH, will present progress for its cosmetic ATR-COSF program targeting the appearance of fine lines and wrinkles. The detailed data will be presented in person at the BIO-Europe® conference in Cologne, Germany on November 1

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By